Αρχειοθήκη ιστολογίου

Κυριακή 1 Απριλίου 2018

Lutetium Lu 177 Dotatate Approved by FDA [News in Brief]

The FDA recently approved the radiopharmaceutical lutetium Lu 177 dotatate to treat patients with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors. The approval was based on results of the phase III NETTER-1 trial.



from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader https://ift.tt/2pXKPdS

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου